Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization

VernacularTitle:抗血管内皮生长因子药物治疗脉络膜新生血管性疾病临床研究应注意的几个问题
Author: Dai HONG
Publication Type:Journal Article
Keywords: Choroidal neovascularization/therapy; Vascular endothelial growth factors; Editorial
From: Chinese Journal of Ocular Fundus Diseases 2011;27(6):503-505
CountryChina
Language:Chinese
Abstract: Anti-vascular endothelial growth factor (VEGF) drugs have become the first-line medications for the treatment of choroidal neovascularization (CNV).Its efficacy and safety have been confirmed by evidence-based medicine and a large number of clinical studies.However there are several issues need to be discussed before reaching a consensus for the clinical application of anti-VEGF drugs.These issues include,but not limited to the individual treatment regimen for different CNV lesions,the best anti-VEGF drug regimen,the indications and schemes of combination therapy,the factors affecting the efficacy,the potential risks of systemic and local deliveries.How to establish a reasonable personalized regimen of anti-VEGF drugs is the 1st issue need to be explored.Ranibizumab will come into China market soon.We need utilize the existing evidence-based medical research findings; take our advantages of rich resources of patients to investigate those issues to further promote the anti-VEGF applications in China.